{"id":6762,"date":"2020-05-08T16:54:14","date_gmt":"2020-05-08T16:54:14","guid":{"rendered":"https:\/\/www.gecp.pt\/?page_id=6762"},"modified":"2020-05-09T18:54:56","modified_gmt":"2020-05-09T18:54:56","slug":"ensaios-gecp","status":"publish","type":"page","link":"https:\/\/www.gecp.pt\/en\/ensaios-gecp\/","title":{"rendered":"GEP\u00b4s CLINICAL TRIALS"},"content":{"rendered":"<p><\/p><!--themify_builder_content-->\n<div id=\"themify_builder_content-6762\" data-postid=\"6762\" class=\"themify_builder_content themify_builder_content-6762 themify_builder tf_clear\">\n                    <div  data-lazy=\"1\" class=\"module_row themify_builder_row tb_q9ku288 tb_first tf_w\">\n                        <div class=\"row_inner col_align_top tb_col_count_1 tf_box tf_rel\">\n                        <div  data-lazy=\"1\" class=\"module_column tb-column col-full tb_56d9288 first\">\n                    <!-- module fancy heading -->\n<div  class=\"module module-fancy-heading tb_v3a3545  tb_hide_divider\" data-lazy=\"1\">\n        <h3 class=\"fancy-heading tf_textc\">\n    <span class=\"main-head tf_block\">\n                    CLINICAL TRIALS            <\/span>\n\n    \n    <span class=\"sub-head tf_block tf_rel\">\n                    GECP            <\/span>\n    <\/h3>\n<\/div>\n<!-- \/module fancy heading -->\n        <\/div>\n                        <\/div>\n        <\/div>\n                        <div  data-lazy=\"1\" class=\"module_row themify_builder_row tb_qc9h794 tf_w\">\n                        <div class=\"row_inner col_align_top tb_col_count_1 tf_box tf_rel\">\n                        <div  data-lazy=\"1\" class=\"module_column tb-column col-full tb_b8jm795 first\">\n                    <!-- module accordion -->\n<div  class=\"module module-accordion tb_6tn2620\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-6tn2620-0\" class=\"tb_title_accordion\" aria-controls=\"acc-6tn2620-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">1.\tProspective study, phase II, to evaluate the efficacy and toxicity of an induction chemotherapy regimen with paclitaxel and carboplatin and concurrent chemotherapy + radiotherapy in radically treatable patients with NSCLC, stage III. <\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-6tn2620-0-content\" data-id=\"acc-6tn2620-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>Presented at the 11\u00ba World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain<\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_75e432\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-75e432-0\" class=\"tb_title_accordion\" aria-controls=\"acc-75e432-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">2.\tDuration of chemotherapy in non-small cell lung carcinoma. Multicentric randomized study of four versus six cycles of carboplatin and gemcitabine <\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-75e432-0-content\" data-id=\"acc-75e432-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>220 patients included<\/li>\n<li>Participation of 10 Centers (CH Coimbra, CH Vila Nova de Gaia, H Sta Maria, H Egas Moniz, CH Vila Real \/ Peso da R\u00e9gua, HSM Braga, IPO Porto, H Pulido Valente, CH Cova da Beira, HSM Guarda)<\/li>\n<li class=\" translation-block\">Presented at the 11th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain (preliminary results)<\/li>\n<li><a href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/Cartaz_GECP_4x6.pdf\" target=\"_blank\" rel=\"noopener\"><strong><span style=\"color: #286fa0;\">Presented at 12th World Conference on Lung Cancer, 2-6 September, Seoul, Korea, 2007 (final results)<\/span><\/strong><\/a><\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_fa8q371\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-fa8q371-0\" class=\"tb_title_accordion\" aria-controls=\"acc-fa8q371-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">Phase II study comparing carboplatin and gemcitabine (continuous perfusion at a constant rate) with carboplatin and gemcitabine (conventional perfusion) as first-line QT for CPNPC, stages IIIB and IV<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-fa8q371-0-content\" data-id=\"acc-fa8q371-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>Presented at 12th World Conference on Lung Cancer, 2-6 September, Seoul, Korea, 2007<\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_kjts929\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-kjts929-0\" class=\"tb_title_accordion\" aria-controls=\"acc-kjts929-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">4.   Phase II, multicentre, randomized clinical study of weekly topotecan versus topotecan in a standard 5 consecutive days reg\u00edmen in the treatment of recurrent small cell lung cancer<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-kjts929-0-content\" data-id=\"acc-kjts929-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <p>...update!<\/p>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_6klc999\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-6klc999-0\" class=\"tb_title_accordion\" aria-controls=\"acc-6klc999-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">5.\tOpen Label, uncontrolled, multicenter phase II study evaluating the efficacy and safety of Cetuximab in combination with cisplatin &amp; gemcitabine as first line therapy in patients with advanced non small cell lung cancer (COIMBRA)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-6klc999-0-content\" data-id=\"acc-6klc999-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>49 patients included<\/li>\n<li>Participation of 6 Centers (CH Coimbra, CH Vila Nova de Gaia, CH Tr\u00e1s os Montes and Alto Douro, H Sta. Maria, HSS, H Pulido Valente)<\/li>\n<li><a href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/Congresso_GECP_ensaio_COIMBRA.pdf\" target=\"_blank\" rel=\"noopener\"><strong><span style=\"color: #286fa0;\">Presented at the 3rd GECP Congress, 23 to 25 October 2008, Albufeira<\/span><\/strong><\/a><\/li>\n<li class=\" translation-block\">Presented at the 13th World Conference on Lung Cancer, July 31 - August 4, 2009. San Francisco, USA<\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_cq3y878\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-cq3y878-0\" class=\"tb_title_accordion\" aria-controls=\"acc-cq3y878-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">6.   Observational study to assess the Quality of Life in patients undergoing 2nd line chemotherapy for Non-Small Cell Lung Cancer (LISBON)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-cq3y878-0-content\" data-id=\"acc-cq3y878-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>219 patients included<\/li>\n<li>Participation of 18 Centers (H. Santa Maria, CH Coimbra, H S.Jo\u00e3o, CH Vila Nova Gaia, IPO Porto, HD Faro, IDP Aveiro, HD Santar\u00e9m, H ES \u00c9vora, CH Tr\u00e1s os Montes and Alto Douro, H Egas Moniz, H Garcia da Orta, HJF Beja, HSM Braga, CH Set\u00fabal, IPO Lisboa, H Pulido Valente, CH Cova da Beira)<\/li>\n<li class=\" translation-block\"><a href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/Estudo_Lisboa_gecp.pdf\" target=\"_self\" rel=\"noopener\"><strong>\tPresented at the 14th World Conference on Lung Cancer, July 3-7 2011, Amsterdam<\/strong><\/a><\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_9eel601\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-9eel601-0\" class=\"tb_title_accordion\" aria-controls=\"acc-9eel601-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">7.   Phase II, open-label study of erlotinib in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (MUTAR)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-9eel601-0-content\" data-id=\"acc-9eel601-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>30 patients included<\/li>\n<li>Participation of 7 Centers (CH S. Jo\u00e3o, CH Vila Nova de Gaia, CH Lisbon North, CH Coimbra, IPO Lisbon, IPO Porto, CH Aveiro)<\/li>\n<li><a href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/Congresso_GECP%20_Poster_MUTAR.pdf\" target=\"_blank\" rel=\"noopener\"><strong><span style=\"color: #286fa0;\">Presented at the 6th Congress of the Lung Cancer Study Group, 9-11 October 2014, Lisbon<\/span><\/strong><\/a><\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_8bqd362\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-8bqd362-0\" class=\"tb_title_accordion\" aria-controls=\"acc-8bqd362-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">8.   Therapeutic options for 3rd line chemotherapy in patients with non-small cell lung cancer who received erlotinib in 2nd line (\u00c9VORA)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-8bqd362-0-content\" data-id=\"acc-8bqd362-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>55 patients included<\/li>\n<li>Participation of 7 Centers (CH Coimbra, IPO Lisbon, H Santa Maria, CH Vila Nova de Gaia \/ Espinho, H S\u00e3o Bernardo, H S\u00e3o Jo\u00e3o, CH Tr\u00e1s-os-Montes and Alto Douro)<\/li>\n<li><a href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/Congresso_SPP_EVORA_Apresentacao_oral_21_10_2013.pdf\" target=\"_blank\" rel=\"noopener\"><strong><span style=\"color: #286fa0;\">Presented at the XXIX Pulmonology Congress, 25-27 October 2013, Epic Sana, Algarve<\/span><\/strong><\/a><\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_plp755\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-plp755-0\" class=\"tb_title_accordion\" aria-controls=\"acc-plp755-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">9.   Determination of the relationship between rapid progression in 2nd line of chemotherapy and response, and of the time until progression in 1st line of chemotherapy, in patients with advanced non-small cell lung cancer (GAIA)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-plp755-0-content\" data-id=\"acc-plp755-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <table width=\"815\">\n<tbody>\n<tr>\n<td style=\"text-align: center;\" width=\"249\">\u00a0 \u00a0 ...update!\u00a0 \u00a0<\/td>\n<td style=\"text-align: center;\" width=\"257\">\n<p>\u00a0<\/p>\n<\/td>\n<td style=\"text-align: center;\" width=\"153\">\u00a0<\/td>\n<td style=\"text-align: center;\" width=\"156\">\n<p>\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion --><!-- module accordion -->\n<div  class=\"module module-accordion tb_uvtk565\" data-behavior=\"toggle\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion   tb_default_color\">\n            <li>\n            <div class=\"accordion-title tf_rel\">\n                <a href=\"#acc-uvtk565-0\" class=\"tb_title_accordion\" aria-controls=\"acc-uvtk565-0-content\" aria-expanded=\"false\">\n                    <i class=\"accordion-icon\"><svg  class=\"tf_fa tf-fas-caret-down\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-down\"><\/use><\/svg><\/i>                    <i class=\"accordion-active-icon tf_hide\"><svg  class=\"tf_fa tf-fas-caret-up\" aria-hidden=\"true\"><use href=\"#tf-fas-caret-up\"><\/use><\/svg><\/i>                    <span class=\"accordion-title-wrap\">10.\tStudy Quality of Way of Lung Cancer patients receiving treatment with antiemetics as a support therapy for chemotherapy (SANTAR\u00c9M)<\/span>                <\/a>\n            <\/div><!-- .accordion-title -->\n            <div id=\"acc-uvtk565-0-content\" data-id=\"acc-uvtk565-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide tf_clearfix\">\n                                    <div class=\"tb_text_wrap\">\n                        <ul>\n<li>124 patients included<\/li>\n<li>Participation of 9 Centers (CH VN Gaia, CH Tr\u00e1s os Montes and Alto Douro, H Braga, H Aveiro, CH Santa Maria, CH Coimbra, CH between Douro and Vouga, IPO Lisbon, H S: Jo\u00e3o)<\/li>\n<li><span style=\"color: #286fa0;\"><a style=\"color: #286fa0;\" href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/_ESTUDO_SANTAREM_gecp.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Presented at the 39th ESMO Congress, 26-30 September 2014, Madrid<\/strong><\/a><\/span><\/li>\n<li><span style=\"color: #286fa0;\"><a style=\"color: #286fa0;\" href=\"https:\/\/www.gecp.pt\/wp-content\/uploads\/ensaios\/GECP-Santarem.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Presented at the 6th Congress of the Lung Cancer Study Group, 9-11 October 2014, Lisbon<\/strong><\/a><\/span><\/li>\n<\/ul>                    <\/div>\n                            <\/div><!-- .accordion-content -->\n        <\/li>\n        <\/ul>\n\n<\/div><!-- \/module accordion -->        <\/div>\n                        <\/div>\n        <\/div>\n        <\/div>\n<!--\/themify_builder_content--><!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>ENSAIOSGECP 1. Estudo Prospectivo, fase II, para avaliar da efic\u00e1cia e toxicidade de um esquema de quimioterapia de indu\u00e7\u00e3o com paclitaxel e carboplatinio e concorrente QT+RT em doentes com CPNPC, est\u00e1dio III, radicalmente trat\u00e1veis. Apresentado no 11\u00ba World Conference on&#8230;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0},"_links":{"self":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/pages\/6762"}],"collection":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/comments?post=6762"}],"version-history":[{"count":20,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/pages\/6762\/revisions"}],"predecessor-version":[{"id":6907,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/pages\/6762\/revisions\/6907"}],"wp:attachment":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media?parent=6762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}